IL6 and neoplasm: Distinct subtypes—such as LRRC15+ myofibroblastic CAFs (myCAFs) implicated in exclusion, versus IL-6-driven inflammatory CAFs (iCAFs)—exhibit divergent effects on tumor immunobiology (183).